Myval与当代THV治疗重度主动脉瓣狭窄的1年结局:LANDMARK试验
LANDMARK试验将768例症状性重度原生主动脉瓣狭窄患者随机分配至Myval球囊扩张式THV系列或当代THV(SAPIEN或Evolut系列),1年复合终点(全因死亡、所有卒中及手术或瓣膜相关住院)无显著差异(87.0% vs 86.9%),Myval非劣效。
要点
- Myval THV系列1年复合终点非劣效于当代THV(差异-0.1%,单侧95%CI 3.9%,P<0.0001)。
- 扩展复合终点(含生活质量)两组无显著差异(80.5% vs 77.3%,P=0.33)。
- 平均年龄80岁,48%女性,STS预测死亡风险中位数2.6%。
核心结论
- 在症状性重度原生主动脉瓣狭窄患者中,Myval THV系列的1年临床和血流动力学结局与当代THV相当。
研究设计与样本
- 开放标签、非劣效性随机对照试验,纳入欧洲、新西兰和巴西31家医院的768例患者,1:1随机接受Myval THV系列或当代THV(SAPIEN或Evolut系列)。
主要发现
- 365天无复合终点事件率Myval组87.0%,当代THV组86.9%,差异-0.1%(单侧95%CI 3.9%,Pnoninferiority<0.0001)。
- 无扩展复合终点事件率Myval组80.5%,当代THV组77.3%,差异3.2%(95%CI -2.9%至9.2%,P=0.33)。
关键数值与推荐
- 1年复合终点包括全因死亡、所有卒中和手术或瓣膜相关住院。
- 扩展复合终点按VARC-3推荐结合12项简表健康调查评估的生活质量。
- 事后探索性非劣效界值为10.89%,基于近期研究事件率27.23%。
临床怎么用
- Myval THV系列可作为症状性重度原生主动脉瓣狭窄的经导管治疗选择之一,1年结局与当代THV相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the LANDMARK trial, the Myval balloon-expandable transcatheter heart valve (THV) series was noninferior to the most commonly used contemporary SAPIEN and Evolut Series THVs for the 30-day early safety endpoint in participants with symptomatic severe native aortic stenosis. OBJECTIVES: The current report from the LANDMARK trial describes clinical outcomes, hemodynamic performances, and quality of life at 1 year. METHODS: This open-label, noninferiority trial enrolled 768 participants across 31 hospitals in Europe, New Zealand, and Brazil. Participants were randomly assigned (1:1) to receive either a Myval THV series or a contemporary THV (SAPIEN or Evolut series). The composite endpoint at 1 year included all-cause mortality, all strokes, and procedure- or valve-related hospitalizations. Clinical efficacy was defined as freedom from the composite endpoint. As recommended in Valve Academic Research Consortium-3, the previous composite endpoint combined with the assessment of quality of life at baseline and 1 year with the 12-Item Short Form Health Survey was reported as an extended composite endpoint. The noninferiority hypothesis was prespecified for the assessment of the primary endpoint at 30 days. Considering the specific 1-year composite endpoints of Valve Academic Research Consortium-3 and the event rate of 27.23% derived from recent studies, an a posteriori descriptive and exploratory noninferiority hypothesis was introduced with a noninferiority margin of 10.89%. The analysis was performed in the intention-to-treat population. RESULTS: The mean age was 80 years, 48% were women, and the median Society of Thoracic Surgeons Predicted Risk of Mortality score was 2.6%. There was no significant difference in the Kaplan-Meier estimates of freedom from the composite endpoint at 365 days (Myval THV 87.0% vs contemporary THVs 86.9%). The Myval THV series was noninferior to the contemporary THVs for the composite endpoint (difference: -0.1%; 1-sided 95% CI: 3.9%; Pnoninferiority < 0.0001). Similarly, there were no significant differences in freedom from the extended composite endpoint (80.5% vs 77.3%; difference: 3.2%; 95% CI: -2.9% to 9.2%; P = 0.33). CONCLUSIONS: In the treatment of symptomatic severe native aortic stenosis, the clinical and hemodynamic outcomes of the Myval THV series were comparable to those of contemporary THVs for the 1-year composite of all-cause mortality, all strokes, or procedure- or valve-related hospitalizations. (LANDMARK Trial: a Randomised Controlled Trial of Myval THV [LANDMARK]; NCT04275726).
引用
- Serruys PW, Tobe A, van Royen N, et al. 1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial. J Am Coll Cardiol. 2025. PMID: 41384893. doi:10.1016/j.jacc.2025.10.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。